LOS ANGELES, Sep. 26 /PRNewswire-FirstCall/ -- NFL Hall of Fame, legendary wide receiver, Fred Biletnikoff, has joined the ever-growing team of celebrated athletes and entertainers as a part of the cardiovascular protection team of Signalife, Inc. (Amex: SGN) and Athletes for Life ("AFL"), using Signalife's Fidelity 100 and its related products and technologies. He has joined such superstars as Joe Theisman, Marshall Faulk, Tim Brown, Rocket Ismail, Jerry Rice, Dwight Clark, and Leonard Marshall in putting down their collective feet to put a stop to the late-stage, inaccurate-diagnosis-laden (diagnoses which is sometimes too little too late) assessment of heart and cardiovascular diseases.
The MVP of Super Bowl XI, Mr. Biletnikoff demonstrated on a world stage what passion and focus mean as he delivered an unprecedented performance in leading his team to an overwhelming victory in the Super Bowl.
In 1999, Mr. Biletnikoff was ranked number 94 on The Sporting News "list of the 100 Greatest Football Players." The Fred Biletnikoff Award, awarded annually to the best wide receiver in college football since 1994, was named in his honor.
Dr. Harmison, former Principal Deputy of the U.S. Department of Health Services, commented: "Mr. Biletnikoff -- one of my personal heroes -- has made the choice to make a difference in a disease-state that burdens practically every family in America and costs the U.S. Health Care industry about $400 billion per year in treating cardiovascular disease. Having someone of his stature -- a true NFL legend -- and of his demographic, will assist Signalife and AFL in addressing all of the different possible disease states and treatment options in a wider array of circumstances. I very much appreciate Mr. Biletnikoff's decision to join our cause to level the playing field for everyone."
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
|SOURCE Signalife, Inc.|
Copyright©2007 PR Newswire.
All rights reserved